Check Out Our Animated Take on the Realities of a "No-deal" Brexit
Our animation explores the challenges that a "no-deal" Brexit poses for the drug development and advanced therapy sectors.
James Strachan |
Back in February we wrote that "hard Brexit looks more likely than ever." Four months later: i) the Withdrawal Agreement (WA) has been rejected in the UK House of Commons for a third time, ii) both candidates for Prime Minister are promising to renegotiate the WA and, if the EU isn’t forthcoming, to leave the EU on October 31 without a deal; and iii) EU leaders are now making it clear that there will be no renegotiation of the WA – and they will not consider another Article 50 extension for the purpose of reopening negotiations on the WA. In short, a hard Brexit appears to be more likely than before.
Our animation covers the basics of how a no-deal Brexit might impact drug developers in the advanced medicines space. For more information, read the full article here.
You can also explore how a no-deal Brexit might impact supply chains.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.